{"id":"insulin-regular-iv-infusion","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin regular is a short-acting human insulin that mimics endogenous insulin secretion. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. When administered intravenously, it provides rapid glucose control suitable for acute hyperglycemia and perioperative management.","oneSentence":"Insulin regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:16.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents insufficient)"},{"name":"Acute hyperglycemia and diabetic ketoacidosis"},{"name":"Perioperative glycemic control"}]},"trialDetails":[{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT07485101","phase":"NA","title":"Glycemic Targets During CPB in Elderly Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-01","conditions":"Glycemic Management During CPB in Elderly Diabetic Cardiac Surgery","enrollment":3000},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT00690066","phase":"PHASE2","title":"PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2008-06-11","conditions":"Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent","enrollment":63},{"nctId":"NCT04958109","phase":"PHASE1","title":"Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-10-28","conditions":"Metabolic Diseases","enrollment":16},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT06624956","phase":"PHASE4","title":"Prevention and Treatment of Common Hyperglycemia in Surgery Pilot","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-09-04","conditions":"Surgery, Non Diabetic Hyperglycemia","enrollment":106},{"nctId":"NCT06111586","phase":"PHASE2","title":"FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2023-12-11","conditions":"Type 1 Diabetes Mellitus","enrollment":192},{"nctId":"NCT07167693","phase":"PHASE1, PHASE2","title":"Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes","status":"RECRUITING","sponsor":"David K Carroll","startDate":"2025-12-19","conditions":"Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes","enrollment":60},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT07398300","phase":"NA","title":"Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03-12","conditions":"Type 2 Diabetes, Healhty","enrollment":36},{"nctId":"NCT06883344","phase":"NA","title":"Automated Insulin for Management of Intrapartum Glycemia","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-12-05","conditions":"Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes","enrollment":150},{"nctId":"NCT07224334","phase":"PHASE1","title":"Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.","status":"RECRUITING","sponsor":"David D'Alessio, M.D.","startDate":"2025-12-30","conditions":"Diabetes (DM)","enrollment":30},{"nctId":"NCT07359625","phase":"NA","title":"Effects of Ketone Bodies on Insulin Sensitivity","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-12-02","conditions":"Insulin Resistance, Obesity & Overweight, Energy Metabolism","enrollment":10},{"nctId":"NCT07326865","phase":"NA","title":"Hepatic Gene Response to Intravenous Glucose in Obese Patients With and Without MASLD Undergoing Bariatric Surgery","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-11-12","conditions":"MASLD","enrollment":40},{"nctId":"NCT03253263","phase":"PHASE2","title":"A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants","status":"RECRUITING","sponsor":"OHB Neonatology Ltd.","startDate":"2019-05-09","conditions":"Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage","enrollment":338},{"nctId":"NCT07300982","phase":"PHASE1, PHASE2","title":"Studies of Insulin and Glucagon Action in the Liver","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-04","conditions":"Diabetes (DM)","enrollment":40},{"nctId":"NCT05389514","phase":"","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Providence Health & Services","startDate":"","conditions":"KRAS G12V Mutant Advanced Epithelial Cancers","enrollment":""},{"nctId":"NCT06090864","phase":"PHASE1, PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":"Hodgkin Lymphoma, Relapse, Refractory","enrollment":31},{"nctId":"NCT06548100","phase":"PHASE3","title":"A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-12-16","conditions":"Generalized Lipodystrophy","enrollment":9},{"nctId":"NCT01803451","phase":"EARLY_PHASE1","title":"Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2005-11","conditions":"Post-bariatric Surgery","enrollment":80},{"nctId":"NCT02244073","phase":"NA","title":"Individualized Blood Glucose Control in ICU. The CONTROLING Study. A Double Blinded Multicentric Randomized Study.","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2015-05","conditions":"Critical Illness","enrollment":2069},{"nctId":"NCT02054429","phase":"PHASE1","title":"Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2013-01","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT03241706","phase":"PHASE1","title":"Liver Glycogen and Hypoglycemia in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jason Winnick","startDate":"2018-08-02","conditions":"Hypoglycemia; Iatrogenic","enrollment":40},{"nctId":"NCT04207619","phase":"NA","title":"Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation","status":"RECRUITING","sponsor":"Pennington Biomedical Research Center","startDate":"2020-02-19","conditions":"Diabetes, Hypoglycemia","enrollment":10},{"nctId":"NCT02103283","phase":"PHASE1","title":"A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-10","conditions":"Diabetic Macular Edema","enrollment":5},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT03912363","phase":"NA","title":"Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids","status":"COMPLETED","sponsor":"Geisinger Clinic","startDate":"2019-11-01","conditions":"Type II Diabetes Mellitus, Gestational Diabetes Mellitus","enrollment":114},{"nctId":"NCT02646475","phase":"PHASE1","title":"Metabolic Effects of Angiotensin-(1-7)","status":"RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-02","conditions":"Obesity, Insulin Resistance, Hypertension","enrollment":26},{"nctId":"NCT01528189","phase":"NA","title":"Effect of High Dose Insulin on Infectious Complications Following Major Surgery","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2018-10-05","conditions":"Surgical Site Infection After Major Surgery","enrollment":460},{"nctId":"NCT06105931","phase":"PHASE1","title":"Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-13","conditions":"type1diabetes, Obesity","enrollment":15},{"nctId":"NCT06424652","phase":"NA","title":"Effect of Physiologic Insulin Administration on Cognition","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2024-05-16","conditions":"Alzheimer Disease","enrollment":1},{"nctId":"NCT05419115","phase":"PHASE2","title":"Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-17","conditions":"Heart Failure","enrollment":170},{"nctId":"NCT00179400","phase":"PHASE4","title":"The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2000-12","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01868997","phase":"PHASE2","title":"Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07","conditions":"Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy","enrollment":88},{"nctId":"NCT06724991","phase":"NA","title":"Lower Vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"University of Malaya","startDate":"2025-01-01","conditions":"Hyperkalemia","enrollment":50},{"nctId":"NCT06652763","phase":"","title":"Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction","status":"RECRUITING","sponsor":"University of Leicester","startDate":"2024-10-10","conditions":"Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes","enrollment":60},{"nctId":"NCT06126419","phase":"NA","title":"Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-08","conditions":"Liver Dysfunction, Liver Metastasis Colon Cancer, Liver Regeneration","enrollment":70},{"nctId":"NCT03660189","phase":"NA","title":"Two Bag System for Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"MetroHealth Medical Center","startDate":"2018-09-17","conditions":"Diabetic Ketoacidosis","enrollment":57},{"nctId":"NCT00630552","phase":"PHASE1, PHASE2","title":"QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2007-06","conditions":"Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer","enrollment":138},{"nctId":"NCT05456854","phase":"PHASE1","title":"Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-06-03","conditions":"Metabolic Disease","enrollment":""},{"nctId":"NCT04532801","phase":"PHASE1","title":"Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance","status":"WITHDRAWN","sponsor":"Stephanie B. Seminara, MD","startDate":"2019-09-01","conditions":"Insulin, Glucose, Healthy Volunteers","enrollment":""},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT04599075","phase":"PHASE4","title":"Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gianna Wilkie","startDate":"2021-03-15","conditions":"Type 1 Diabetes, Pregnancy, High Risk","enrollment":70},{"nctId":"NCT06007508","phase":"PHASE2","title":"Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2022-05-31","conditions":"DKA","enrollment":8},{"nctId":"NCT03175978","phase":"PHASE1, PHASE2","title":"IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"IGF Oncology, LLC","startDate":"2018-02-21","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, With Excess of Blasts","enrollment":2},{"nctId":"NCT06265415","phase":"NA","title":"Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2024-03-30","conditions":"Severe Preeclampsia","enrollment":60},{"nctId":"NCT04946552","phase":"NA","title":"Sympathetic Activation in Obesity","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-11-23","conditions":"Obesity, Healthy","enrollment":5},{"nctId":"NCT03449251","phase":"PHASE2","title":"A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-03-28","conditions":"Cardiovascular Diseases, Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT06116188","phase":"","title":"Brain Insulin Resistance in Mild Cognitive Impairment","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2023-10-12","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Positron Emission Tomography","enrollment":40},{"nctId":"NCT00858897","phase":"NA","title":"Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2007-06","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT00673309","phase":"PHASE2, PHASE3","title":"Assessment of Mechanisms of Improved Wound Healing","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2000-07","conditions":"Burns","enrollment":644},{"nctId":"NCT01397279","phase":"NA","title":"Assessment of Liver Glucose Metabolism in Diabetic Subjects","status":"COMPLETED","sponsor":"German Diabetes Center","startDate":"2011-07","conditions":"Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)","enrollment":22},{"nctId":"NCT03665207","phase":"PHASE3","title":"Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"KU Leuven","startDate":"2018-09-18","conditions":"Critical Illness, Hyperglycemia","enrollment":9230},{"nctId":"NCT02032953","phase":"PHASE4","title":"Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2013-12","conditions":"Colorectal Cancer","enrollment":24},{"nctId":"NCT02102243","phase":"PHASE4","title":"Neural Mechanism of Aldosterone-induced Insulin Resistance","status":"WITHDRAWN","sponsor":"Wanpen Vongpatanasin","startDate":"2010-11","conditions":"Hypertension","enrollment":""},{"nctId":"NCT03195400","phase":"","title":"Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-03-01","conditions":"IGT - Impaired Glucose Tolerance, T2D","enrollment":100},{"nctId":"NCT02371226","phase":"PHASE1","title":"Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I","status":"COMPLETED","sponsor":"ArmaGen, Inc","startDate":"2015-07","conditions":"Mucopolysaccharidosis I","enrollment":3},{"nctId":"NCT04567225","phase":"PHASE4","title":"Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-10-01","conditions":"Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes","enrollment":39},{"nctId":"NCT04886973","phase":"NA","title":"Effect of Insulin Resistance on Branched Chain Amino Acid Metabolism.","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2022-03-31","conditions":"Obesity, Insulin Resistance","enrollment":40},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT02930044","phase":"NA","title":"Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-10","conditions":"Diabetic Ketoacidosis","enrollment":18},{"nctId":"NCT00214916","phase":"PHASE2","title":"Tight Glycemic Control With Intensive Insulin Therapy in PICU","status":"UNKNOWN","sponsor":"Greet Van den Berghe","startDate":"2004-10","conditions":"Critical Illness","enrollment":700},{"nctId":"NCT05155917","phase":"PHASE2","title":"Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care","status":"UNKNOWN","sponsor":"Changhua Christian Hospital","startDate":"2022-03-01","conditions":"Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycaemic Hyperosmolar Nonketotic Syndrome","enrollment":70},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT04558190","phase":"NA","title":"Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2020-09-02","conditions":"Insulin Resistance","enrollment":10},{"nctId":"NCT02936687","phase":"PHASE1","title":"Mechanisms of Cerebrovascular Control","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-01-31","conditions":"Metabolic Syndrome X","enrollment":59},{"nctId":"NCT03204344","phase":"NA","title":"Preoperative Oral Carbohydrate and Postoperative Recovery in Diabetic Patients","status":"COMPLETED","sponsor":"Dong-Xin Wang","startDate":"2017-08-01","conditions":"Gastrointestinal Surgery","enrollment":65},{"nctId":"NCT01096784","phase":"PHASE2","title":"IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-18","conditions":"Retinopathy of Prematurity (ROP)","enrollment":121},{"nctId":"NCT03028571","phase":"PHASE1","title":"Autonomic Blockade and Endogenous Glucose Production","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2017-04-17","conditions":"Insulin Resistance","enrollment":""},{"nctId":"NCT04347252","phase":"PHASE1","title":"Glucagon Regulation of Glucose Metabolism","status":"COMPLETED","sponsor":"David D'Alessio, M.D.","startDate":"2019-09-24","conditions":"Insulin Secretion","enrollment":19},{"nctId":"NCT01327612","phase":"PHASE2","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03-03","conditions":"Advanced Solid Tumors, Carcinoid, Colorectal Cancer","enrollment":12},{"nctId":"NCT00642941","phase":"PHASE2","title":"A Study of R1507 in Participants With Recurrent or Refractory Sarcoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-12-18","conditions":"Sarcoma","enrollment":317},{"nctId":"NCT04712266","phase":"EARLY_PHASE1","title":"A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Abvance Therapeutics","startDate":"2020-09-15","conditions":"Type 1 Diabetes Mellitus With Hypoglycemia","enrollment":15},{"nctId":"NCT04299815","phase":"NA","title":"Lactate in the Gut","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2020-04-01","conditions":"Lactate, Healthy, Hyperlactatemia","enrollment":10},{"nctId":"NCT02548494","phase":"NA","title":"Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes","status":"TERMINATED","sponsor":"Chattanooga-Hamilton County Hospital Authority","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 1, Diabetic Ketoacidosis","enrollment":17},{"nctId":"NCT03330314","phase":"PHASE1","title":"Molar Potency Study of HM12460A in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2017-10-24","conditions":"Healthy Volunteers","enrollment":38},{"nctId":"NCT02398383","phase":"EARLY_PHASE1","title":"Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Cystic Fibrosis, Cystic Fibrosis Related Diabetes","enrollment":7},{"nctId":"NCT00279305","phase":"PHASE2","title":"Rituximab in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-08","conditions":"Type 1 Diabetes Mellitus","enrollment":87},{"nctId":"NCT00100178","phase":"PHASE2","title":"New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 1","enrollment":126},{"nctId":"NCT03234751","phase":"PHASE1","title":"Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects","status":"COMPLETED","sponsor":"AdventHealth Translational Research Institute","startDate":"2017-07-13","conditions":"Diabetes","enrollment":6},{"nctId":"NCT02206152","phase":"PHASE1, PHASE2","title":"A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-02","conditions":"Type 1 Diabetes, Hypoglycemia Unawareness","enrollment":22},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT03170544","phase":"PHASE1","title":"Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-08-16","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT02321111","phase":"PHASE2","title":"The Role of TLR4 on Lipid-induced Insulin Resistance","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-01","conditions":"Insulin Sensitivity","enrollment":10},{"nctId":"NCT03461510","phase":"NA","title":"Type 2 Diabetes and the Brain in Adolescents","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2017-12-05","conditions":"Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity","enrollment":18},{"nctId":"NCT03520153","phase":"","title":"Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2018-08-07","conditions":"McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm","enrollment":""},{"nctId":"NCT02045368","phase":"PHASE1","title":"Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R","status":"COMPLETED","sponsor":"IGF Oncology, LLC","startDate":"2014-01-28","conditions":"Breast Cancer, Brain Cancer, Gastrointestinal Cancers","enrollment":92},{"nctId":"NCT03223129","phase":"NA","title":"Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2018-01-09","conditions":"Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT03912480","phase":"EARLY_PHASE1","title":"Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function","status":"UNKNOWN","sponsor":"CAR-T (Shanghai) Biotechnology Co., Ltd.","startDate":"2019-01-05","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT03095651","phase":"PHASE1","title":"Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-12","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT02109029","phase":"PHASE1","title":"A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT00816361","phase":"PHASE1","title":"A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03-09","conditions":"Cancer","enrollment":43},{"nctId":"NCT01498952","phase":"PHASE1","title":"MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-01-17","conditions":"Unresectable or Metastatic Hepatocellular Carcinoma (HCC)","enrollment":6},{"nctId":"NCT02269735","phase":"PHASE1","title":"A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11-26","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT02406586","phase":"NA","title":"Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)","status":"COMPLETED","sponsor":"Emory University","startDate":"2009-07","conditions":"Hypertension, Diabetes","enrollment":36},{"nctId":"NCT00394524","phase":"NA","title":"Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Diabetes or With New Hyperglycemia","enrollment":160},{"nctId":"NCT02597114","phase":"PHASE1","title":"Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181","status":"COMPLETED","sponsor":"ArmaGen, Inc","startDate":"2015-11","conditions":"Mucopolysaccharidosis I","enrollment":3},{"nctId":"NCT02059174","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-10","conditions":"Type 1 Diabetes Mellitus","enrollment":76},{"nctId":"NCT00845039","phase":"PHASE2","title":"A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2009-05","conditions":"Colon Cancer, Rectal Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":228,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"insulin regular IV infusion","genericName":"insulin regular IV infusion","companyName":"Rush University Medical Center","companyId":"rush-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents insufficient), Acute hyperglycemia and diabetic ketoacidosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}